insights_auto
Why is KYNB down 2.92%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
$6.31
arrow_downward
-2.92%(-0.19) 1D
$6.30
arrow_downward
-0.16% (-0.0100)bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$6.60
High
$6.64
Low
$6.30
Mkt. cap
25.55M
Avg. vol.
25.22K
Volume
26.08K
P/E ratio
0.14
52-wk high
$9.70
52-wk low
$6.30
EPS
$45.30
Beta
1.05
Shares outstanding
4.05M
No. of employees
34
Open
$6.60
High
$6.64
Low
$6.30
Mkt. cap
25.55M
Avg. vol.
25.22K
Volume
26.08K
P/E ratio
0.14
52-wk high
$9.70
52-wk low
$6.30
EPS
$45.30
Beta
1.05
Shares outstanding
4.05M
No. of employees
34
News stories
From web sources and news partners
The Motley Fool
·
7 minutes ago
The S&P 500 Hasn't Looked This Cheap Based on a Popular Metric in Decades. Should You Buy Stocks Now?
Stock Traders Daily
·
4 hours ago
(TDIV) Price Dynamics and Execution-Aware Positioning
Simply Wall Street
·
1 hour ago
3 Consumer Staples Stocks Tied To Rising Pet Care Spending
Business Insider
·
1 day ago
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitekyntrabio.com